CI · CIK 1739940
What The Cigna Group told the SEC could break it.
Cigna's disclosures point first to concentration in its pharmacy-benefit business: a single pharmacy-benefit client was about 19% of total external revenue in 2025 (reported in its Evernorth segment), and U.S. Federal Government agencies have run 11–15% of external revenue. Layered on that is a financial structure that limits flexibility — roughly $31.5 billion of total debt dedicates cash flow to servicing it, while statutory rules on its insurance subsidiaries (a $4.5B minimum surplus and caps of $2.0B on dividends and $1.2B on loans to the parent without approval in 2026) restrict cash reaching the holding company. It also flags strategic-execution complexity across its pharmacy and health-care businesses, pointing to its $2.7 billion full impairment of VillageMD in 2024.
4 self-disclosed vulnerabilities, pulled from its own filings — each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Customer concentration
- single pharmacy-benefit client ~19% of external revenue (Evernorth); U.S. Federal Government agencies 11-15%medium
Revenues from a single pharmacy-benefit client were ~19% of Cigna's total revenue from external customers in 2025 (16% in 2024), reported in Evernorth Health Services; separately, U.S. Federal Government agencies were 11% (2024) and 15% (2023) of external revenue — material client/payer concentration in the PBM business.
“Revenues from a single pharmacy benefit client were approximately 19% and 16% of total revenue from external customers for the years ended December 31, 2025 and 2024, respectively. These amounts were reported in the Evernorth Health Services segment.”
SEC filing →As of 2026
Liquidity & debt
- high leverage — ~$31.5B total indebtednessmedium
The Cigna Group's total indebtedness was ~$31.5 billion as of December 31, 2025; carrying this debt dedicates cash flow to debt service (reducing funds for operations/growth), increases vulnerability to adverse economic/industry conditions, and may limit access to capital.
“The total indebtedness of The Cigna Group was approximately $31.5 billion as of December 31, 2025.”
SEC filing →As of 2026
Regulatory & policy
- insurance-subsidiary statutory restrictions — $4.5B min surplus; $2.0B max dividend / $1.2B max parent loans without approvalmedium
Cigna's insurance subsidiaries are subject to regulatory capital constraints: $4.5B minimum statutory surplus required, $0.3B on deposit with regulators, and without regulatory approval in 2026 a maximum of $2.0B in dividend distributions and $1.2B in loans to the parent — with $11.3B of restricted GAAP net assets — limiting cash available to the holding company.
“Minimum statutory surplus required by regulators (1) $ 4.5 ... Maximum dividend distributions permitted in 2026 without regulatory approval $ 2.0 Maximum loans to the parent company permitted without regulatory approval $ 1.2 Restricted GAAP net assets of subsidiaries of The Cigna Group $ 11.3”
SEC filing →As of 2026
Other disclosures
- strategic-execution complexity across pharmacy & health-care businesses; VillageMD $2.7B impairment (2024)low
Cigna's future performance depends on executing strategic/operational initiatives whose risk is heightened by the complexity across its pharmacy-services and health-care businesses; in 2024 it recorded a $2.7B loss fully impairing its VillageMD investment, illustrating the downside of strategic bets.
“in the year ended December 31, 2024, we determined our investment in VillageMD was fully impaired and recorded a $2.7 billion loss in Net investment gains/losses ... Strategic execution risk may be heightened by the complexity across our pharmacy services and health care businesses.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings — including ones disclosed by the other side, which is how the non-obvious ones come to light.
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch